The emergence of designed multiple ligands for neurodegenerative disorders

Progress in Neurobiology

Volumn 94, Issue 4, 2011, Pages 347-359

  Geldenhuys, Werner J ^a   Youdim, Moussa B H ^b,c   Carroll, Richard T ^a   Van der Schyf, Cornelis J ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Yonsei University   (South Korea)

Author keywords

HLA20 HLA20A; Homobivalent carbolines; Istradefylline KW6002; L 3 n butylphthalide; Ladostigil; Memoquin; MitoNEET; NGP1 01; Pioglitazone; Rasagiline; Resveratrol

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 3 BUTYLPHTHALIDE; 4 [4 [2 [(5 HYDROXY 1,2,3,4 TETRAHYDRONAPHTHALEN 2 YL)(PROPYL)AMINO]ETHYL]PIPERAZIN 1 YL]QUINOLIN 8 OL DERIVATIVE; 4 BENZYL 3 HYDROXY 4 AZAHEXACYCLO[5.4.1.0 2,6 .0 3,10 .0 5,9 .0 8,11]DODECANE; ADENOSINE A2A RECEPTOR; BETA CARBOLINE DERIVATIVE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; HLA 20; HLA 20 A; IRON CHELATING AGENT; ISTRADEFYLLINE; LADOSTIGIL; LIGAND; M 10; MEMANTINE; MEMOQUIN; MEMOQUIN DERIVATIVE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PIOGLITAZONE; RASAGILINE; RESVERATROL; ROSIGLITAZONE; SCAVENGER; TV 1022; UNCLASSIFIED DRUG; UNINDEXED DRUG; VK 28;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DIZZINESS; DROWSINESS; DRUG DESIGN; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HYPERACTIVITY; INFLAMMATION; INSOMNIA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; STROKE;

AMYLOID BETA-PEPTIDES; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 79960217061     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.04.010     Document Type: Review

References (131)

1. Albani D., Polito L., Forloni G. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J. Alzheimers Dis. 2010, 19:11-26.
2. Amenta F., Tayebati S.K. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr. Med. Chem. 2008, 15:488-498.
3. Andrews J.M., Ninan P.T., Nemeroff C.B. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 1996, 4:48-56.
4. Ankerst J. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma. J. Asthma. 2005, 42:715-724.
5. Barbiero J.K., Santiago R.M., Lima M.M., Ariza D., Morais L.H., Andreatini R., Vital M.A. Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav. Brain Res. 2011, 216:186-192.
6. Blanchet J., Longpre F., Bureau G., Morissette M., DiPaolo T., Bronchti G., Martinoli M.G. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1243-1250.
7. Bolognesi M.L., Banzi R., Bartolini M., Cavalli A., Tarozzi A., Andrisano V., Minarini A., Rosini M., Tumiatti V., Bergamini C., Fato R., Lenaz G., Hrelia P., Cattaneo A., Recanatini M., Melchiorre C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J. Med. Chem. 2007, 50:4882-4897.
8. Bolognesi M.L., Bartolini M., Rosini M., Andrisano V., Melchiorre C. Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action. Bioorg. Med. Chem. Lett. 2009, 19:4312-4315.
9. Bolognesi M.L., Bartolini M., Tarozzi A., Morroni F., Lizzi F., Milelli A., Minarini A., Rosini M., Hrelia P., Andrisano V., Melchiorre C. Multitargeted drugs discovery: Balancing anti-amyloid and anticholinesterase capacity in a single chemical entity.Bioorg. Med. Chem. Lett. 2010, 10.1016/j.physletb.2003.10.071.
10. Bolognesi M.L., Cavalli A., Bergamini C., Fato R., Lenaz G., Rosini M., Bartolini M., Andrisano V., Melchiorre C. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J. Med. Chem. 2009, 52:7883-7886.
11. Bolognesi M.L., Cavalli A., Melchiorre C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics 2009, 6:152162.
12. Bolognesi M.L., Matera R., Minarini A., Rosini M., Melchiorre C. Alzheimer's disease: new approaches to drug discovery. Curr. Opin. Chem. Biol. 2009, 13:303-308.
13. Bolognesi M.L., Rosini M., Andrisano V. MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond. Curr. Pharm. Des. 2009, 15:601-613.
14. Bordet R., Ouk T., Petrault O., Gele P., Gautier S., Laprais M., Deplanque D., Duriez P., Staels B., Fruchart J.C., Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. 2006, 34:1341-1346.
15. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
16. Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51:347-372.
17. Chen H.S., Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 2006, 97:1611-1626.
18. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli N., Schwarzschild M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 2001, 21:RC143.
19. Chen J.J., Swope D.M., Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin. Ther. 2007, 29:1825-1849.
20. Chen Y.F., Kao C.H., Kirby R., Tsai T.F. Cisd2 mediates mitochondrial integrity and life span in mammals. Autophagy 2009, 5:1043-1045.
21. Colca J.R., McDonald W.G., Waldon D.J., Leone J.W., Lull J.M., Bannow C.A., Lund E.T., Mathews W.R. Identification of a novel mitochondrial protein (" mitoNEET" ) cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E252-E260.
22. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 2006, 530:70-80.
23. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 2000, 20:558-567.
24. Culman J., Zhao Y., Gohlke P., Herdegen T. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol. Sci. 2007, 28:244-249.
25. Dall'Igna O.P., Porciuncula L.O., Souza D.O., Cunha R.A., Lara D.R. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br. J. Pharmacol. 2003, 138:1207-1209.
26. Dall'Igna O.P., Souza D.O., Lara D.R. Caffeine as a neuroprotective adenosine receptor antagonist. Ann. Pharmacother. 2004, 38:717-718.
27. Dinamarca M.C., Arrázola M., Toledo E., Cerpa W.F., Hancke J., Inestrosa N.C. Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice. Chem. Biol. Interact. 2008, 175:142-149.
28. Dinamarca M.C., Sagal J.P., Quintanilla R.A., Godoy J.A., Arrázola M.S., Inestrosa N.C. Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease. Mol. Neurodegener. 2010, 5:4.
29. Doyle A.E. Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients?J. Hypertens. Suppl. 1988, 6:S51-53.
30. Fernandez, H.H., Greeley, D.R., Zweig, R.M., Wojcieszek, J., Mori, A., Sussman, N.M., 2009. Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial. Parkinsonism Relat Disord.
31. Foster A.C., Gill R., Iversen L.L., Kemp J.A., Wong E.H., Woodruff G.N. Therapeutic potential of NMDA receptor antagonists as neuroprotective agents. Prog. Clin. Biol. Res. 1990, 361:301-329.
32. Gautier S., Petrault O., Gele P., Laprais M., Bastide M., Bauters A., Deplanque D., Jude B., Caron J., Bordet R. Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke 2003, 34:2975-2979.
33. Geldenhuys W.J., Darvesh A.S., Funk M.O., Van der Schyf C.J., Carroll R.T. Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorg. Med. Chem. Lett. 2010, 20:5295-5298.
34. Geldenhuys W.J., Funk M.O., Barnes K.F., Carroll R.T. Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET. Bioorg. Med. Chem. Lett. 2010, 20:819-823.
35. Geldenhuys W.J., Malan S.F., Bloomquist J.R., Van der Schyf C.J. Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor. Bioorg. Med. Chem. 2007, 15:1525-1532.
36. Ghosh B., Antonio T., Reith M.E.A., Dutta A.K. Discovery of 4-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)-ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: In vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's Disease. J. Med. Chem. 2010, 53:2114-2125.
37. Hao J., Mdzinarishvili A., Abbruscato T.J., Klein J., Geldenhuys W.J., Van der Schyf C.J., Bickel U. Neuroprotection in mice by NGP1-01 after transient focal brain ischemia. Brain Res. 2008, 1196:113-120.
38. Hauser R.A., Shulman L.M., Trugman J.M., Roberts J.W., Mori A., Ballerini R., Sussman N.M. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov. Disord. 2008, 23:2177-2185.
39. Haycox A., Armand C., Murteira S., Cochran J., Francois C. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation. Drugs Aging 2009, 26:791-801.
40. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., Landreth G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128:1442-1453.
41. Herrine S.K., Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann. Intern. Med. 1999, 130:163-164.
42. Higgins G.A., Ballard T.M., Enderlin M., Haman M., Kemp J.A. Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacology (Berl.) 2005, 179:85-98.
43. Honda T., Kaikita K., Tsujita K., Hayasaki T., Matsukawa M., Fuchigami S., Sugiyama S., Sakashita N., Ogawa H., Takeya M. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J. Mol. Cell. Cardiol. 2008, 44:915-926.
44. Imai S.I. A possibility of nutriceuticals as an anti-aging intervention: Activation of sirtuins by promoting mammalian NAD biosynthesis. Pharmacol. Res. 2010, 62:42-47.
45. Inestrosa N.C., Dinamarca M.C., Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J. 2008, 275:625-632.
46. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov. 2006, 5:247-264.
47. Jain K.K. Evaluation of memantine for neuroprotection in dementia. Expert Opin. Investig. Drugs 2000, 9:1397-1406.
48. Jenner P., Mori A., Hauser R., Morelli M., Fredholm B.B., Chen J.F. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:406-413.
49. Ji S., Kronenberg G., Balkaya M., Farber K., Gertz K., Kettenmann H., Endres M. Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome. Exp. Neurol. 2009, 216:321-328.
50. Joghataie M.T., Roghani M., Negahdar F., Hashemi L. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat. Disord. 2004, 10:465-468.
51. Kaundal R.K., Iyer S., Kumar A., Sharma S.S. Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils. J. Pharmacol. Sci. 2009, 109:361-367.
52. Kemp J.A., McKernan R.M. NMDA receptor pathways as drug targets. Nat. Neurosci. 2002, 5Suppl:1039-1042.
53. Kennedy G.J. From symptom palliation to disease modification: Implications for dementia care. Prim. Psych. 2007, 14:30-34.
54. Kiewert C., Hartmann J., Stoll J., Thekkumkara T.J., Van der Schyf C.J., Klein J. NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels. Neurochem. Res. 2006, 31:395-399.
55. Kummer M.P., Heneka M.T. PPARs in Alzheimer's Disease. PPAR Res. 2008, 2008:403896.
56. Küppers E., Ivanova T., Karolczak M., Beyer C. Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons. J. Neurocytol. 2000, 29:375-385.
57. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
58. Lee S.R., Kim H.Y., Hong J.S., Baek W.K., Park J.W. PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. Biochem. Biophys. Res. Commun. 2009, 380:17-21.
59. León R., Marco-Contelles J. A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-β aggregation and Ca(2+) dyshomeostasis. Curr. Med. Chem. 2011, 18:552-576.
60. LeWitt P.A., Guttman M., Tetrud J.W., Tuite P.J., Mori A., Chaikin P., Sussman N.M. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces " off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 2008, 63:295-302.
61. Li J., Lang M.J., Mao X.B., Tian L., Feng Y.B. Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of rat. Cardiovasc. Drugs Ther. 2008, 22:283-291.
62. Li L., Sengupta A., Haque N., Grundke-Iqbal I., Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004, 566:261-269.
63. Lin J., Zhou T., Ye K., Wang J. Crystal structure of human mitoNEET reveals distinct groups of iron sulfur proteins. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14640-14645.
64. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 2006, 5:160-170.
65. Lu K.T., Ko M.C., Chen B.Y., Huang J.C., Hsieh C.W., Lee M.C., Chiou R.Y., Wung B.S., Peng C.H., Yang Y.L. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem. 2008, 56:6910-6913.
66. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martinez A., Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 2005, 280:21453-21462.
67. Maia L., de Mendonca A. Does caffeine intake protect from Alzheimer's disease?. Eur. J. Neurol. 2002, 9:377-382.
68. Maruyama W., Nitta A., Shamoto-Nagai M., Hirata Y., Akao Y., Yodim M., Furukawa S., Nabeshima T., Naoi M. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem. Int. 2004, 44:393-400.
69. Mdzinarishvili A., Geldenhuys W.J., Abbruscato T.J., Bickel U., Klein J., Van der Schyf C.J. NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neurosci. Lett. 2005, 383:49-53.
70. Millan M.J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 2006, 110:135-370.
71. Miranda S., Opazo C., Larrondo L.F., Muñoz F.J., Ruiz F., Leighton F., Inestrosa N.C. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog. Neurobiol. 2000, 62:633-648.
72. Morelli M., Carta A.R., Jenner P. Adenosine A2A receptors and Parkinson's disease. Handb. Exp. Pharmacol. 2009, 589-615.
73. Morphy R., Kay C., Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov. Today 2004, 9:641-651.
74. Morphy R., Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48:6523-6543.
75. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., Langston W., Melamed E., Poewe W., Stocchi F., Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 2009, 361:1268-1278.
76. Paddock M.L., Wiley S.E., Axelrod H.L., Cohen A.E., Roy M., Abresch E.C., Capraro D., Murphy A.N., Nechushtai R., Dixon J.E., Jennings P.A. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14342-14347.
77. Patzer A., Zhao Y., Stock I., Gohlke P., Herdegen T., Culman J. Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur. J. Neurosci. 2008, 28:1786-1794.
78. Peng Y., Xing C., Lemere C.A., Chen G., Wang L., Feng Y., Wang X. l-3-n-Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells. Neurosci. Lett. 2008, 434:224-229.
79. Peng Y., Xing C., Xu S., Lemere C.A., Chen G., Liu B., Wang L., Feng Y., Wang X. L-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-beta peptide in rats. Eur. J. Pharmacol. 2009, 621:38-45.
80. Peng Y., Sun J., Hon S., Nylander A.N., Xia W., Feng Y., Wang X., Lemere C.A. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. J. Neurosci. 2010, 30:8180-8189.
81. Peng Y., Hu Y., Xu S., Feng N., Wang L., Wang X. L-3-n-Butylphthalide regulates amyloid precursor protein processing by PKC and MAPK pathways in SK-N-SH cells over-expressing wild type human APP695. Neurosci. Lett. 2011, 487:211-216.
82. Peters J.M., Aoyama T., Burns A.M., Gonzalez F.J. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim. Biophys. Acta 2003, 1632:80-89.
83. Prediger R.D., Batista L.C., Takahashi R.N. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiol. Aging 2005, 26:957-964.
84. Prediger R.D., Pamplona F.A., Fernandes D., Takahashi R.N. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) -- the spontaneously hypertensive rat (SHR). Int. J. Neuropsychopharmacol. 2005, 8:583-594.
85. Quinn L.P., Crook B., Hows M.E., Vidgeon-Hart M., Chapman H., Upton N., Medhurst A.D., Virley D.J. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br. J. Pharmacol. 2008, 154:226-233.
86. Rammes G., Rupprecht R., Ferrari U., Zieglgänsberger W., Parsons C.G. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanesantagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci. Lett. 2001, 306:81-84.
87. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003, 348:1333-1341.
88. Rennings A.J., Meijer P., van Uden D.J., Tack C.J., Smits P., Boerman O.C., Oyen W.J., Rongen G.A. Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome. Eur. Heart J. 2009.
89. Riederer P., Danielczyk W., Grunblatt E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 2004, 25:271-277.
90. Roecklein B.A., Sacks H.J., Mortko H., Stables J. Fluorofelbamate. Neurotherapeutics 2007, 4:97-101.
91. Rook Y., Schmidtke K.U., Gaube F., Schepmann D., Wünsch B., Heilmann J., Lehmann J., Winckler T. Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J. Med. Chem. 2010, 53:3611-3617.
92. Sagi Y., Weinstock M., Youdim M.B. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem. 2003, 86:290-297.
93. Saluja I., Granneman J.G., Skoff R.P. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 2001, 33:191-204.
94. Saura J., Luque J.M., Cesura A.M., Da Prada M., Chan-Palay V., Huber G., Loffler J., Richards J.G. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994, 62:15-30.
95. Schapira A.H., Olanow C.W. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann. Neurol. 2008, 64(Suppl 2):S47-55.
96. Shachar D.B., Kahana N., Kampel V., Warshawsky A., Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004, 46:254-263.
97. Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H., Greenberg J.H. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005, 36:353-359.
98. Song M.S., Rauw G., Baker G.B., Kar S. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur. J. Neurosci. 2008, 28:1989-2002.
99. Sramek J.J., Cutler N.R. Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging 1999, 14:359-373.
100. Van Boxtel M.P., Schmitt J.A., Bosma H., Jolles J. The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacol. Biochem. Behav. 2003, 75:921-927.
101. Van der Schyf C.J. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev. Clin. Pharmacol. 2011, 4:293-298.
102. Van der Schyf C.J., Mandel S., Geldenhuys W.J., Amit T., Avramovich Y., Zheng H., Fridkin M., Gal S., Weinreb O., Bar Am O., Sagi Y., Youdim M.B. Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties. Curr. Alzheimer Res. 2007, 4:522-536.
103. Van der Schyf C.J., Squier G.J., Coetzee W.A. Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist. Pharmacol. Res. Commun. 1986, 18:407-417.
104. Weinreb O., Amit T., Bar-Am O., Yogev-Falach M., Youdim M.B. The neuroprotective mechanism of action of the multimodal drug ladostigil. Front Biosci. 2008, 13:5131-5137.
105. Weinreb O., Amit T., Bar-Am O., Youdim M.B. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. N.Y. Acad. Sci. 2007, 1122:155-168.
106. Weinreb O., Bar-Am O., Amit T., Drigues N., Sagi Y., Youdim M.B. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem. Biol. Interact. 2008, 175:318-326.
107. Weinreb O., Mandel S., Bar-Am O., Yogev-Falach M., Avramovich-Tirosh Y., Amit T., Youdim M.B. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics 2009, 6:163-174.
108. Weinstock M., Luques L., Poltyrev T., Bejar C., Shoham S. Ladostigil prevents age-related glial activation and spatial memory deficits in rats. Neurobiol. Aging 2009.
109. Wiley S.E., Murphy A.N., Ross S.A., van der Geer P., Dixon J.E. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:5318-5323.
110. Wiley S.E., Paddock M.L., Abresch E.C., Gross L., van der Geer P., Nechushtai R., Murphy A.N., Jennings P.A., Dixon J.E. The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster. J. Biol. Chem. 2007, 282:23745-23749.
111. Wong E.H., Tarazi F.I., Shahid M. The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. Pharmacol. Ther. 2010, 126:173-185.
112. Wu J.S., Cheung W.M., Tsai Y.S., Chen Y.T., Fong W.H., Tsai H.D., Chen Y.C., Liou J.Y., Shyue S.K., Chen J.J., Chen Y.E., Maeda N., Wu K.K., Lin T.N. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 2009, 119:1124-1134.
113. Xi J., Wang H., Mueller R.A., Norfleet E.A., Xu Z. Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. Eur. J. Pharmacol. 2009, 604:111-116.
114. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 2003, 23:7504-7509.
115. Yi J.H., Park S.W., Brooks N., Lang B.T., Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 2008, 1244:164-172.
116. Yogev-Falach M., Amit T., Bar-Am O., Weinstock M., Youdim M.B. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 2002, 16:1674-1676.
117. Youdim M.B., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M., Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 2005, 79:172-179.
118. Youdim M.B., Buccafusco J.J. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J. Neural. Transm. 2005, 112:519-537.
119. Youdim M.B., Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 2005, 26:27-35.
120. Youdim M.B., Fridkin M., Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech. Ageing Dev. 2005, 126:317-326.
121. Youdim M.B., Riederer P.F. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 2004, 63:S32-35.
122. Youdim M.B., Riederer P.F. Monoamine oxidase A and B inhibitors in Parkinson's disease. Handb. Clin. Neurol. 2007, 84:93-120.
123. Yu H.C., Feng S.F., Chao P.L., Lin A.M. Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system. Neuropathol. Appl. Neurobiol. 2010.
124. Zdanys K., Tampi R.R. A systematic review of off-label uses of memantine for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1362-1374.
125. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863-873.
126. Zheng H., Weiner L.M., Bar-Am O., Epsztejn S., Cabantchik Z.I., Warshawsky A., Youdim M.B., Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 2005, 13:773-783.
127. Zheng H., Youdim M.B., Fridkin M. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's Therapy. J. Med. Chem. 2009, 52:4095-4098.
128. Zheng H., Youdim M.B., Weiner L.M., Fridkin M. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem. Pharmacol. 2005, 70:1642-1652.
129. Zheng H., Youdim M.B.H., Fridkin M. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem. Biol. 2010, 5:603-610.
130. Zhu W., Xie W., Pan T., Jankovic J., Li J., Youdim M.B., Le W. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J. Neurochem. 2008, 105:1970-1978.
131. Zimmermann G.R., Lehar J., Keith C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12:34-42.